Rivera-Rodríguez L, Cline B

Language: Spanish
References: 10
Page: 51-53
PDF size: 64.03 Kb.

ABSTRACT

Congenital heart disease is associated with arrhythmias. Not only the congenital anatomic component but also the greater arrhythmogenic substrate related to surgical procedures is associated with the increased incidence of arrhythmias in these patients. In pediatric cardiology the study of these phenomena is becoming important and one factor associated with it is the longer follow up, which varies depending on the type of heart disease and arrhythmia. With the same impact, there are daily breakthroughs in diagnostic and treatment through pharmacological and interventional means. The incidence of arrhythmias in post-surgical patients with congenital heart disease is in constant increment, and this is related to the constant increment in the procedures, variety and frequency, as well as the long-term survival.

REFERENCES

1. Bigger JT, Fleiss JL, Kleiger R, et al: The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation 1984; 69: 250-258.

2. Hohnsloser SH, Klingenheben T, Zabel M, et al: Prevalence, characteristics and prognostic value during long-term follow-up of NSVT after MI in the thromboloytic era. J Am Coll Cardiol 1999; 1895-1902.

3. Hallstrom A, P.C., Greene HL, Huther M, et al: Relations between heart failure, ejection fraction, arrhythmia suppression and mortality: analysis of the Cardiac arrhythmia Suppression Trial. J Am Coll Cardiol 1995; 25(6): 1250-1257.

4. Copie X, H.K., Staunton A, Fei L, et al: Predictive power of increased heart rate versus depressed left ventricular ejection fraction and heart rate variability for risk stratification after myocardial infarction. Results of a two-year follow-up study. J Am Coll Cardiol 1996. 27(2): 270-276.

5. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329 (22):1615.

6. Rouleau JL, Talajic M, Sussex B, et al: Myocardial Infarction Patients in the 1990s-Their Risk factors, Stratification and Survival in Canada: The Canadian Assessment of Myocardial Infarction (CAMI) Study. J Am Coll Cardiol 1996; 27: 1119-1127.

7. Buxton AE, Lee KL, DiCarlo L, et al: Nonsustained ventricular tachycardia in coronary artery disease: relation to inducible sustained ventricular tachycardia. Ann Intern Med. 1996; 125: 35-39.

8. Every NR, Hlatky MA, McDonald KM, et al: Estimating the proportion of post-myocardial infarction patients who may benefit from prophylactic implantable defibrillator placement from analysis of the CAST registry. Am J Cardiol. 1998; 82(5): 683-685.

9. Grönefeld G, Connolly SJ, Hohnloser SH: The Defibrillator in Acute Myocardial Infarction Trial (DINAMIT): Rationale, Design and Specific Aims. Card Electrophysiol Rev 2003; 7: 447-451.

10. Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R, Fain E, Gent M, Connolly SJ; DINAMIT Investigators. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004; 351(24): 2481-8.